Reduction of costs

It is anticipated that N2B-patch may reduce direct treatment costs due to a considerable lower intranasal dose.

API is not lost on its way to the central nervous system and is thus not “wasted”.

We will produce the N2B-patch applicator via cost-effective injection moulding productions, making it generally affordable.

Furthermore, it is expected that reduced disability may lead to a direct reduction in the costs of nursing care and most likely, a reduction of indirect costs also. Therefore, it is anticipated that N2B-patch may not only have a considerable positive impact for European citizens and MS patients, but may consequentially reduce the burden on the costs of the European health and social care systems